CXCR4 and cancer: Consequently, in vivo, the CXCR4 peptide antagonist TN14003 displaces CXCR4+ cancer cells from their niche, rendering them sensitive to apoptotic induction, an observation that could be replicated in vitro when cancer cells are co-cultured with SDF1α-expressing stromal cells [78].